NZ597563A - Muc1 antibodies - Google Patents

Muc1 antibodies

Info

Publication number
NZ597563A
NZ597563A NZ597563A NZ59756310A NZ597563A NZ 597563 A NZ597563 A NZ 597563A NZ 597563 A NZ597563 A NZ 597563A NZ 59756310 A NZ59756310 A NZ 59756310A NZ 597563 A NZ597563 A NZ 597563A
Authority
NZ
New Zealand
Prior art keywords
chain variable
variable region
antibody
disclosed
heavy chain
Prior art date
Application number
NZ597563A
Other languages
English (en)
Inventor
Steffen Goletz
Uwe Karsten
Antje Danielczyk
Renate Stahn
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of NZ597563A publication Critical patent/NZ597563A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ597563A 2009-07-31 2010-07-30 Muc1 antibodies NZ597563A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Publications (1)

Publication Number Publication Date
NZ597563A true NZ597563A (en) 2013-08-30

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597563A NZ597563A (en) 2009-07-31 2010-07-30 Muc1 antibodies

Country Status (17)

Country Link
US (1) US9217038B2 (cg-RX-API-DMAC7.html)
EP (3) EP2281844A1 (cg-RX-API-DMAC7.html)
JP (2) JP5922018B2 (cg-RX-API-DMAC7.html)
KR (1) KR101773506B1 (cg-RX-API-DMAC7.html)
CN (1) CN102574926B (cg-RX-API-DMAC7.html)
AR (1) AR077334A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010278302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002226A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768888C (cg-RX-API-DMAC7.html)
CU (1) CU23972B1 (cg-RX-API-DMAC7.html)
EA (1) EA029954B1 (cg-RX-API-DMAC7.html)
IL (1) IL217827A (cg-RX-API-DMAC7.html)
MX (1) MX2012000874A (cg-RX-API-DMAC7.html)
NZ (1) NZ597563A (cg-RX-API-DMAC7.html)
SG (2) SG177527A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011012309A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200166B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2603528B1 (en) 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CN105008550B (zh) * 2013-03-01 2018-03-30 学校法人埼玉医科大学 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015119180A1 (ja) * 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン4(muc4)糖ペプチドに対する抗体及びその用途
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗muc1抗体又はその抗原結合性断片及びその用途
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトMUC1抗体Fabフラグメント
JP7162011B2 (ja) * 2017-01-18 2022-10-27 ナノクルーズ・ファーマシューティカル・リミテッド 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
CN110382541A (zh) 2017-03-29 2019-10-25 葛莱高托普有限公司 人源化抗cd40抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
KR102832078B1 (ko) * 2017-10-24 2025-07-08 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc1抗体およびその使用
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗muc1抗體-藥物結合物投予的藥劑低敏感性癌之治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1993020841A1 (en) 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Muc−1抗原に対する治療用抗体およびその使用方法
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Also Published As

Publication number Publication date
CN102574926B (zh) 2014-10-15
IL217827A0 (en) 2012-03-29
KR20120051724A (ko) 2012-05-22
CA2768888A1 (en) 2011-02-03
US20120128676A1 (en) 2012-05-24
EP2281844A1 (en) 2011-02-09
AU2010278302A1 (en) 2012-02-09
IL217827A (en) 2017-05-29
SG10201404019XA (en) 2014-09-26
SG177527A1 (en) 2012-02-28
EP3421497A1 (en) 2019-01-02
EA201270207A1 (ru) 2012-07-30
AR077334A1 (es) 2011-08-17
WO2011012309A8 (en) 2011-04-07
MX2012000874A (es) 2012-02-01
JP2016041771A (ja) 2016-03-31
CU20120019A7 (es) 2012-06-21
BR112012002226A2 (pt) 2016-11-08
JP6272916B2 (ja) 2018-01-31
WO2011012309A1 (en) 2011-02-03
CU23972B1 (es) 2013-12-27
CN102574926A (zh) 2012-07-11
KR101773506B1 (ko) 2017-08-31
JP5922018B2 (ja) 2016-05-24
AU2010278302B2 (en) 2014-12-18
ZA201200166B (en) 2013-03-27
US9217038B2 (en) 2015-12-22
JP2013500703A (ja) 2013-01-10
EP2459595A1 (en) 2012-06-06
EA029954B1 (ru) 2018-06-29
CA2768888C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
WO2009048537A3 (en) Humanized antibody
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases
NZ594682A (en) Fully human antibodies specific to cadm1
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
EA201290173A1 (ru) Антитела против эндоглина
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
IL186948A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
MX345092B (es) Anticuerpos anti-tau humanos,.
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
MX2013001102A (es) Diacuerpos covalentes y sus usos.
GB201005064D0 (en) Biological products
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
NZ597611A (en) Anti notch-1 antibodies
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2017 BY PAVIS EG

Effective date: 20140724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2018 BY PAVIS GMBH

Effective date: 20170721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2019 BY PAVIS GMBH

Effective date: 20180720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2020 BY PAVIS GMBH

Effective date: 20190717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20200724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20220720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2025 BY PAVIS PAYMENTS GMBH

Effective date: 20240715

ASS Change of ownership

Owner name: DAIICHI SANKYO COMPANY, JP

Effective date: 20250507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2026 BY PAVIS PAYMENT GMBH

Effective date: 20250718